12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Company News  |  Deals

Pieris, Daiichi Sankyo deal

Pieris will use its Anticalin scaffold technology to discover Anticalin candidates against two undisclosed targets selected by Daiichi. Anticalins are engineered proteins with antibody-like binding properties....

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >